Zev Binder, M.D., Ph.D.
Research Assistant Professor of Neurosurgery
Scientific Director, Adult Brain Tumor Tissue Bank
Instructor, Department of Neurosurgery
Perelman School of Medicine
University of Pennsylvania
Department: Neurosurgery
Contact information
3600 Hamilton Walk
Stemmler Hall
Philadelphia, PA 19104
Stemmler Hall
Philadelphia, PA 19104
Office: 215-573-0837
Publications
Links
Search PubMed for articles
O'Rourke Laboratory Website
University of Pennsylvania's Center for Cellular Immunotherapies
Search PubMed for articles
O'Rourke Laboratory Website
University of Pennsylvania's Center for Cellular Immunotherapies
Education:
BS (Biochemistry)
University of California, Davis, 2004.
M.D.
Pennsylvania State University College of Medicine, 2008.
Ph.D. (Chemical and Biomolecular Engineering)
Johns Hopkins University, 2014.
Permanent linkBS (Biochemistry)
University of California, Davis, 2004.
M.D.
Pennsylvania State University College of Medicine, 2008.
Ph.D. (Chemical and Biomolecular Engineering)
Johns Hopkins University, 2014.
Description of Research Expertise
Dr. Binder is a Research Assistant Professor, working with Dr. O'Rourke since 2015. He received a B.S. degree in Biochemistry from the University of California at Davis, an M.D. from Pennsylvania State University, and a Ph.D. in Chemical and Biomolecular Engineering from Johns Hopkins University. Dr. Binder's research focuses on translational GBM research with an emphasis on immuno-oncology. He also works on GBM model development, characterization, and incorporation into the ongoing research.Selected Publications
Edward Z.Song Xin Wang Benjamin I. Philipson Qian Zhang Radhika Thokala Logan Zhang Charles-Antoine Assenmacher Zev A. Binder Guo-li Ming Donald M. O’Rourke Hongjun Song Michael C. Milone: The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity. Molecular Therapy - Oncolytics 27, December 2022.Benjamin Lin, Julia Ziebro, Erin Smithberger, Kasey R Skinner, Eva Zhao, Timothy F Cloughesy, Zev A Binder, Donald M O'Rourke, David A Nathanson, Frank B Furnari, C Ryan Miller: EGFR, the Lazarus target for precision oncology in glioblastoma. Neuro-Oncology September 2022.
Bakas S, Sako C, Akbari H, Bilello M, Sotiras A, Shukla G, Rudie JD, Santamaria NF, Kazerooni AF, Pati S, Rathore S, Mamourian E, Ha SM, Parker W, Doshi J, Baid U, Bergman M, Binder ZA, Verma R, Lustig RA, Desai AS, Bagley SJ, Mourelatos Z, Morrissette J, Watt CD, Brem S, Wolf RL, Melhem ER, Nasrallah MP, Mohan S, O’Rourke DM, Davatzikos C. : The University of Pennsylvania glioblastoma (UPenn-GBM) cohort: advanced MRI, clinical, genomics, & radiomics. Scientific Data July 2022.
Pierre-Emmanuel Bonte, Yago A. Arribas, Antonela Merlotti, Montserrat Carrascal, Jiasi Vicky Zhang, Elina Zueva, Zev A. Binder, Cecile Alanio, Christel Goudot, and Sebastian Amigorena: Single-cell RNA-seq-based proteogenomics identifies glioblastoma-specific transposable elements encoding HLA-I-presented peptides. Cell Reports 39, June 2022.
Tang OY, Tian L, Chang WJ, Yoder T, Melenhorst JJ, Lacey SF, O’Rourke DM*, Binder ZA*: Characteristics of EGFRvIII-Directed CAR T Cell Infusion Product Associated with Clinical Response in Recurrent Glioblastoma. Frontiers in Immunology May 2022.
Yin Y, Rodriguez JS, Li N, Thokala R, Nasrallah MP, Hu L, Zhang L, Zhang JV, Kainth D, Haddad L, Johns EX, Long Y, Liang H, Qi J, Zhang X, Binder ZA*, Lin Z*, O’Rourke DM*: Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogenous solid tumors. Molecular Therapy May 2022.
Alanio C*, Binder ZA*, Chang R*, Nasrallah MP*, Delman D, Li J, Tang O, Zhang L, Zhang JV, Wherry EJ, O’Rourke DM, Beatty GL: Evolution of immunological features from de novo to recurrence associates with survival outcomes in patients with glioblastoma. Cancer Immunology Research May 2022.
Zev A. Binder and Donald M. O'Rourke: Glioblastoma: The Current State of Biology and Therapeutic Strategies. Cancer Research 82(5), March 2022.
Oliver Tang, Zev A. Binder, Lifeng Tian, Wan-Jung Chang, Todd Yoder, Simon Lacey, J. Jos Melenhorst, and Donald M. O’Rourke: Characteristics of EGFRvIII-directed CAR T cell infusion product associated with clinical response in recurrent glioblastoma. Society for Neuro-Oncology 26th Annual Scientific Meeting November 2021 Notes: Poster presentation.
Thokala R*, Binder ZA*, Yin Y, Zhang L, Zhang JV, Zhang DY, Milone MC, Ming G, Song H, O’Rourke DM.: High Affinity Chimeric Antigen Receptor with Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms. Frontiers in Oncology September 2021.